Functionally, EBF1 downregulation promotes the acquisition of stem cell-like traits and tumorigenic potential in cholangiocytes, enhances their resistance to oxidative damage, and increases responsiveness to estrogenic stimulation—all contributing to CCA progression. The gene discussed is EBF1; the disease is cholangiocarcinoma.